<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">95104</article-id><article-id pub-id-type="doi">10.26442/2075-1753_2018.9.71-75</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Dexketoprofen: therapeutic potential in neurology</article-title><trans-title-group xml:lang="ru"><trans-title>Декскетопрофен: возможности применения в неврологии</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Pilipovich</surname><given-names>A. A</given-names></name><name xml:lang="ru"><surname>Пилипович</surname><given-names>Анна Александровна</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, доц. каф. нервных болезней ИПО</p></bio><email>aapilipovich@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый МГМУ им. И.М.Сеченова»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2018-09-15" publication-format="electronic"><day>15</day><month>09</month><year>2018</year></pub-date><volume>20</volume><issue>9</issue><issue-title xml:lang="en">VOL 20, NO9 (2018)</issue-title><issue-title xml:lang="ru">ТОМ 20, №9 (2018)</issue-title><fpage>71</fpage><lpage>75</lpage><history><date date-type="received" iso-8601-date="2021-12-28"><day>28</day><month>12</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/95104">https://consilium.orscience.ru/2075-1753/article/view/95104</self-uri><abstract xml:lang="en"><p>At present non-steroid anti-inflammatory drugs (NSAID) remain the basis for acute pain syndrome of any intensity treatment. In clinical neurologysts' practice NSAID are mostly used in musculoskeletal system disorders treatment and for headaches abortion. The concern is to choose a right medication for the patient considering all indications and contraindications, to determine an adequate dosage or a combination of several analgetic drugs. In the meantime it is recommended to use medications with maximal rate of analgesic effect development and minimal risk of adverse effects in gastrointestinal tract development without loss of effectiveness. Dexketoprofen trometamol, a dextrarotatory isomer of ketoprophen, is one of these medications from NSAID group. The drug is highly purified from R(-)-ketoprophen (99.9%), and has improved physico-chemical properties. The article describes its mechanisms of action, and presents clinical studies results that demonstrate dexketoprofen trometamol (Dexalgin®) analgetic effectiveness and tolerance with the primary indication for use in neurology in musculoskeletal pain and migrainous headaches treatment.</p></abstract><trans-abstract xml:lang="ru"><p>На сегодняшний день основой терапии острого болевого синдрома любой степени выраженности остаются нестероидные противовоспалительные препараты (НПВП). В практике клинического невролога наиболее часто НПВП используются для лечения заболеваний опорно-двигательного аппарата и купирования головных болей. Задача заключается в том, чтобы правильно выбрать препарат для пациента, учитывая все показания и противопоказания, адекватно подобрать дозу или комбинацию нескольких анальгетиков. При этом желательно использовать препарат с максимальной скоростью развития противоболевого эффекта и минимальным риском осложнений со стороны желудочно-кишечного тракта без ущерба для эффективности. Одним из таких представителей группы НПВП является декскетопрофена трометамол - правовращающий изомер кетопрофена. Препарат обладает высокой степенью очистки от R(-)-кетопрофена (99,9%), имеет улучшенные физико-химические свойства. В статье разбираются механизмы его действия, приводятся данные клинических исследований, демонстрирующие анальгетическую эффективность и переносимость декскетопрофена трометамола (препарат Дексалгин®) по основному показанию к применению препарата в неврологии - скелетно-мышечные боли, а также головные боли мигренозного характера.</p></trans-abstract><kwd-group xml:lang="en"><kwd>back pain</kwd><kwd>musculoskeletal pain</kwd><kwd>dexketoprofen trometamol</kwd><kwd>Dexalgin</kwd><kwd>migraine</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>боль в спине</kwd><kwd>скелетно-мышечные боли</kwd><kwd>декскетопрофена трометамол</kwd><kwd>Дексалгин</kwd><kwd>мигрень</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Алексеев В.В., Баринов А.Н., Кукушкин М.Л. и др. Боль. Руководство для врачей и студентов. Под ред. Н.Н.Яхно. М.: Медпресс-информ, 2009.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Рябоконь И.В. Современный взгляд на лечение боли в спине. Справочник поликлинического врача. 2009; 3: 78-81.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Mauleon D, Artigas R, Garcнa M.L, Carganico G. Preclinical and clinical development of dexketoprofen. Drugs 1996; 52 (Suppl. 5): 24-45.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Barbanoj M.J, Gich I, Artigas R et al. Pharmacokinetics of dexketoprofen trometamol in healthy volunteers after single and repeated oral doses. Drugs 1998; 52 (Suppl. 5): 24-45.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>McEwen J, De Luca M, Casini A et al. The effect of food and an antacid on the bioavailability of dexketoprofen trometamol. J Clin Pharmacol 1998; 38 (Suppl. 12): 33S-40S.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Карнеев А.Н. Практика лечения боли в спине. Consilium Medicum. 2017; 19 (2.2. Неврология и Ревматология): 32-6.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Moore R.A, Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol 2008; 8: 11.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Zippel H, Wagenitz A. Comparison of the efficacy and safety of intravenously administered dexketoprofen trometamol and ketoprofen in the management of pain after orthopaedic surgery: A multicentre, double-blind, randomised, parallelgroup clinical trial. Clin Drug Investig 2006; 26: 517-28.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Zapata A, Cegarra F, Artigas R, Keller F. Dexketoprofen vs tramadol: randomised double-blind trial in patients with postoperative pain. British J Clin Pharmacol 2000; 223: abs 870.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Hanna M.H, Elliott K.M, Stuart-Taylor M.E et al. Comparative study of analgesic efficacy and morphine-sparing effect of intramuscular dexketoprofen trometamol with ketoprofen or placebo after major orthopaedic surgery. Br J Clin Pharmacol 2003; 55: 126-133.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Jackson I.D, Heidemann B.H, Wilson J et al. Doubleblind, randomized, placebo-controlled trial comparing rofecoxib with dexketoprofen trometamol in surgical dentistry. Br J Anaesth 2004; 92: 675-80.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>McGurk M, Robinson P, Rajayogeswaran V et al. Clinical comparison of dexketoprofen trometamol, ketoprofen, and placebo in postoperative dental pain. J Clin Pharmacol 1998; 38 (Suppl. 12): 46S-54S.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Munoz G, Berini L, Sanchez S et al. Preoperative dexketoprofen trometamol for the prevention of postoperative dental pain: a randomised double-blind clinical trial. Method Find Exp Clin Pharmacol 1998; 20 (Suppl A): 69.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Sanchez-Carpena J, Dominguez-Hervella F, Garcia I et al; Dexketoprofen Renal Colic Study Group. Comparison of intravenous dexketoprofen and dipyrone in acute renal colic. Eur J Clin Pharmacol 2007; 63 (8): 751-60.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zippel H, Wagenitz A. A multicentre, randomised, double-blind study comparing the efficacy and tolerability of intramuscular dexketoprofen versus diclofenac in the symptomatic treatment of acute low back pain. Clin Drug Investig 2007; 27: 533-43.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Metscher B, Kubler U, Jahnel-Kracht H. Dexketoprofen-trometamol and tramadol in acute lumbago. Fortschr Med Orig 2001; 118: 147-51.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Marenco J.L, Pérez M, Navarro F.J et al. A multicentre, randomised, double-blind study to compare the efficacy and tolerability of dexketoprofen trometamol versus diclofenac in the symptomatic treatment of knee osteoarthritis. Clin Drug Invest 2000; 19: 247-56.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Ezcurdia M, Cortejoso F.J, Lanzon R et al. Comparison of the efficacy and tolerability of dexketoprofen and ketoprofen in the treatment of primary dysmenorrhea. J Clin Pharmacol 1998; 38 (Suppl. 12): 65S-73S.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Rodriguez M.J, Contreras D, Galvez R et al. Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain 2003; 104: 103-10.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Leman P, Kapadia Y, Herington J. Randomised controlled trial of the onset of analgesic efficacy of dexketoprofen and diclofenac in lower limb injury. Emerg Med J 2003; 20: 511-3.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Beltra’n J et al. Comparison of Dexketoprofen trometamol and ketoprofen in the treatment of osteoartritis of the knee. J Clin Pharmacol 1998; 38: 74S-80S.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Capriai A, Mas M, Bertoloti M et al. Intramuscular dexketoprofen trometamol in acute lower back pain. 10th World Congress on Pain, IASP, California, 2002; p. 108-12.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Metscher B, Kubler U et al. Dexketoprofen-trometamol and tramadol in acute lumbago. Fortschr Med Orig 2001; 118 (4): 147-51.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Подчуфарова Е.В. Опыт применения препарата Дексалгин® при лечении острых скелетно-мышечных болевых синдромов. Эффективная фармакотерапия. Неврология и Психиатрия. 2012; 2: 34-9.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Меркулов Ю.А., Меркулова Д.М., Крыжановский Г.Н. Эффективность дексалгина на вертеброгенные и невертеброгенные механизмы дизрегуляции при болях в спине. Журн. неврологии и психиатрии им. С.С.Корсакова. 2006; 106 (5): 20-4.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Соловьева Э.Ю., Карнеев А.Н., Федин А.И. Сочетанное применение дексалгина и нимесила в стадии обострения дорсопатии. Врач. 2007; 3: 67-71.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Подчуфарова Е.В., Яхно Н.Н. Боли в спине и конечностях. В кн.: Болезни нервной системы. Руководство для врачей. Под ред. Н.Н.Яхно. Т. 2. М., 2005; с. 306-31</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Krymchantowski A.V, Jevoux C.C. The experience of combining agents, specially triptans and non steroidal anti-inflammatory drugs, for the acute treatment of migraine - a review. Recent Pat CNS Drug Discov 2007; 2: 141-4.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Tullo V, Valguarnera F, Barbanti P et al. Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: A randomized study. Cephalalgia 2014; 34: 434-45.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Allais G, Rolando S, Schiapparelli P et al. Frovatriptan plus dexketoprofen in the treatment of menstrually related migraine. An open study. Neurol Sci 2013; 34 (Suppl. 1): S179-S181.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Elkind A.H and MacGregor E.A. Frovatriptan for the acute treatment of migraine and prevention of predictable menstrual migraine. Expert Rev Neurother 2008; 8: 723-36.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Allais G, Bussone G, Tullo V et al. Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial. Cephalalgia 2015; 35 (1): 45-50.</mixed-citation></ref></ref-list></back></article>
